Abstract: The present invention provides methods for differentially diagnosing rheumatoid arthritis (RA) versus psoriatic arthritis (PsA) in an individual. Specifically, the method relates to detecting the presence or absence of distinct alleles of the PDE4D and PDE4B genes which are associated with either RA or PsA. Also provided herein are methods for selecting an individual who should receive or who is likely to respond to a treatment with a PDE4 inhibitor. The present invention also provides methods for treating an individual with RA or PsA.

Abstract: This invention provides methods for predicting response to anti-TNF? biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.

Abstract: Provided herein are methods for predicting a response to anti-TNF? biologic treatment in patients suffering from rheumatoid arthritis (RA). The methods can be used to discriminate or categorize patients as likely to respond to a monoclonal antibody-based anti-TNF? biological inhibitor, but not likely to respond to an antibody fragment-based anti-TNF? biological inhibitor or a TNF receptor-based biological inhibitor. Alternatively, the methods are also useful to determine whether patients with RA are likely to respond to an antibody fragment-based anti-TNF? biological inhibitor or a TNF receptor-based biological inhibitor, but not likely to respond to a monoclonal antibody-based anti-TNF? biological inhibitor. Also provided are methods for treating a patient with RA based on the patient's level of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide autoantibody (ACPA) relative to reference control levels.

Abstract: In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-? factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.

Abstract: In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-? factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.